Sermorelin vs CJC-1295: the two GHRH analogs compared
Both stimulate endogenous growth hormone release via GHRH receptors. One has historical FDA approval and legal compounding; the other is Category 2. Mechanisms, half-lives, and regulatory paths differ meaningfully.
Sermorelin and CJC-1295 are both synthetic analogs of growth-hormone-releasing hormone (GHRH), the natural hypothalamic peptide that triggers pulsatile GH release from the pituitary. They differ in molecular modification strategy (sermorelin is a GHRH fragment; CJC-1295 with DAC adds albumin-binding for extended half-life), legal status (sermorelin is legally compoundable; CJC-1295 is Category 2), and dosing frequency (daily vs weekly for DAC).
| Field | Sermorelin | CJC-1295 (with DAC) |
|---|---|---|
| Brand names | Geref (discontinued); now compounded | |
| Manufacturer | Various compounding pharmacies | Research-peptide vendors |
| FDA approved | Historical FDA approval (1997, pediatric GH deficiency); commercial withdrawn 2008 | Not FDA approved; Category 2 (Sep 2023); Feb 2026 HHS proposed removal |
| Indication | Pediatric GH deficiency (historical); off-label adult use for GH decline | Research use; biohacker GH-axis stacks |
| Mechanism | GHRH 1-29 fragment; stimulates pulsatile GH release | Modified GHRH 1-29 with DAC (drug affinity complex) for albumin binding; extended half-life |
| Delivery | Daily subcutaneous injection | Weekly subcutaneous injection (DAC) or daily (without DAC) |
Frequently asked
Which one is legal in the US right now?
Sermorelin is legally compoundable via 503A pharmacies with a prescription. CJC-1295 is FDA Category 2 (September 2023), meaning US compounding pharmacies cannot legally prepare it. The February 2026 HHS proposal may change this for CJC-1295 pending FDA review.
What's the difference between CJC-1295 with and without DAC?
DAC (Drug Affinity Complex) is a technology that tethers the peptide to serum albumin, extending half-life from minutes (without DAC) to ~7 days (with DAC). Without DAC, CJC-1295 is a daily injection matching short GHRH pulses. With DAC, it's a sustained GHRH receptor activator dosed weekly.
Does sustained GHRH activation (CJC-1295 DAC) have safety implications vs pulsatile (sermorelin)?
Theoretically, yes — natural GH secretion is pulsatile for reasons that may matter biologically. Chronically elevated IGF-1 carries theoretical cancer-risk concerns common to the class. Rigorous long-term comparative human data is limited.
Which is better for anti-aging use in adults?
Neither has FDA approval for that indication. The evidence that either produces meaningful quality-of-life improvements in healthy adults is thin. Sermorelin has the legal advantage (compoundable), but neither is backed by strong Phase 3 data for adult wellness use cases.